Other content in this Stream
Preparing for Success: A Better Way to Manage the Feasibility Process
A maturity model for site feasibility.
Quiz: The State of the Site Selection & Feasibility Industry
Reinventing Site Feasibility: Moving from Simple Survey to Relationship Management
Best Practices in Site Feasibility Studies Can Set the Stage for a Healthy Trial
Flip the Funnel: Rethinking Patient Recruitment
Unlocking the Full Potential of Your Patient Recruitment ROI
<p>WCG Institute Fellow, Mark Summers, WCG's President of Patient Engagement, discusses best practices for forecasting patient enrollment through the Concentric Circle Framework. This is part one of a
10 Tough Patient Recruitment Questions, Answered.
Solving The Problem of Clinical Research Enrollment
Examine the conditions that affect enrollment and learn strategies to increase it.
Six Practices of High Performing Clinical Research Sites
Learn what high-performing research sites have in common, and what makes sponsors return to them again and again.
Early Chart Reviews Can Provide Steady Flow of Potential Study Subjects, Experts Say
Data-Driven Site Selection: Accelerating Your Trials Through Predictive Site Modeling
Finding New Solutions to a Current Unsustainable Model of Clinical Trial Contracts & Budgets
Five Essential Considerations For Efficient Site Contracts and Payments
Innovation in Investigator Site Contracting
4 Tips to Bolster Your Regulatory Strategy
Q&A: The Role of Expert Committees and the Regulatory Landscape
Dr. Seltzer, president and founder of ACI Clinical, and chief scientific officer of WCG Clinical, shared his insights on expert committees during a recent conversation with Bill Stedman.
The Role of Expert Committees: An interview with Dr. Seltzer
What’s the role of expert committees today? What’s happening on the regulatory side? Dr. Seltzer, Chief Scientific Officer of WCG Clinical, shared his insights on expert committees during a recent...
DMC Regulations May Change, but Principles Won't
Centralized adjudication of cardiovascular end points in cardiovascular and noncardiovascular pharrmacologic trials